Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

Small molecule inhibitors of PARP1/2 such as olaparib have been proposed to serve as a synthetic lethal therapy for cancers that harbor BRCA1 or BRCA2 mutations. Indeed, in clinical trials PARP1/2 inhibitors elicit sustained anti-tumor responses in patients with germ-line BRCA gene mutations. In hyp...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer Res
मुख्य लेखकों: Bajrami, Ilirjana, Frankum, Jessica R., Konde, Asha, Miller, Rowan E., Rehman, Farah L., Brough, Rachel, Campbell, James, Sims, David, Rafiq, Rumana, Hooper, Sean, Chen, Lina, Kozarewa, Iwanka, Assiotis, Ioannis, Fenwick, Kerry, Natrajan, Rachael, Lord, Christopher J., Ashworth, Alan
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2013
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4886090/
https://ncbi.nlm.nih.gov/pubmed/24240700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-2541
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन